Pills masthead

Archives: Search / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

2011201020092008200720062004

 
From
To
Apr 22, 2021
Lannett Announces Closing Of $350 Million Senior Secured Notes And $190 Million Second Lien Senior Secured Loan Facility

Lannett Company, Inc. (NYSE: LCI) today announced the closing of the $350 million aggregate principal amount of 7.750% senior secured notes due 2026 (the "Notes") in a private placement to...

More
Apr 9, 2021
Lannett Announces Pricing Of $350 Million Senior Secured Notes Due 2026

Lannett Company, Inc. (NYSE: LCI) (the "Company" or "Lannett") today announced the pricing of the $350 million aggregate principal amount of 7.75% senior secured notes due 2026 (the "Notes") in a...

More
Apr 6, 2021
Lannett Announces Offering Of $350 Million Senior Secured Notes Due 2026

Lannett Company, Inc. (NYSE: LCI) (the "Company") today announced that it intends to offer, subject to market conditions and other factors, $350 million aggregate principal amount of senior...

More
Apr 1, 2021
Lannett Submits ANDA For Generic ADVAIR DISKUS®

Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Abbreviated New Drug Application (ANDA) for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg...

More
Mar 10, 2021
Lannett Development Of Biosimilar Insulin Glargine Product Continues To Advance

Lannett Company, Inc. (NYSE: LCI) today announced that it recently received feedback from the U.S. Food and Drug Administration (FDA) regarding biosimilar insulin glargine, a product the company...

More
Feb 9, 2021
Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin

Lannett Company, Inc. (NYSE: LCI) today announced that it has added a new co-development agreement for biosimilar insulin aspart with its strategic alliance partners within the HEC Group of...

More
Feb 8, 2021
Lannett Begins Marketing Chlorpromazine Hydrochloride Tablets

Lannett Company, Inc. (NYSE: LCI) today announced that it has begun marketing Chlorpromazine Hydrochloride Tablets, USP, 10 mg, 25 mg, 50 mg, 100 mg and 200 mg. The company recently received...

More
Feb 3, 2021
Lannett Announces Fiscal 2021 Second-Quarter Financial Results In Line Or Above Expectations

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 second quarter ended December 31, 2020. "For the fiscal 2021 second quarter, net sales exceeded our...

More
Jan 27, 2021
Lannett To Report Fiscal 2021 Second-Quarter Financial Results, Host Conference Call On Wednesday, February 3

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 second quarter on Wednesday, February 3, 2021, after the market closes. Lannett...

More
Dec 7, 2020
Lannett Announces New $30 Million Revolving Credit Facility

Lannett Company, Inc. (NYSE: LCI) today announced the closing of a $30 million asset-backed revolving credit facility with Wells Fargo Bank, National Association. "Completing this transaction...

More
Nov 30, 2020
Lannett Pays Off, In Full, Remaining Term A Loans

Lannett Company, Inc. (NYSE: LCI) today announced that the company used a portion of its existing cash on hand to pay off, in full, the remaining $42 million outstanding balance of its Term A...

More
Nov 4, 2020
Lannett Announces Fiscal 2021 First-quarter Financial Results; Affirms Guidance

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 first quarter ended September 30, 2020. "We view our fiscal 2021 first quarter net sales of $126 million as a...

More
Nov 3, 2020
Lannett Launches Authorized Generic of Tirosint® (Levothyroxine Sodium Capsules)

Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced the launch of the authorized generic of Tirosint® (Levothyroxine Sodium Capsules USP). Lannett entered into an exclusive...

More
Oct 28, 2020
Lannett To Report Fiscal 2021 First-Quarter Financial Results, Host Conference Call On Wednesday, November 4

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 first quarter on Wednesday, November 4, 2020, after the market closes. Lannett...

More
Aug 26, 2020
Lannett Announces Fiscal 2020 Fourth-Quarter, Full-Year Financial Results

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 fourth quarter and full year ended June 30, 2020. "For both the fiscal 2020 full year and fourth quarter, our...

More
Aug 19, 2020
Lannett To Report Fiscal 2020 Fourth-Quarter, Full-Year Financial Results, Host Conference Call On Wednesday, August 26

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 fourth quarter and full year on Wednesday, August 26, 2020, after the market closes....

More
Aug 17, 2020
Lannett Announces Notice Of Proposed Settlement And Dismissal With Prejudice Of Derivative Action

Lannett Company, Inc. (NYSE: LCI) today announced the Notice of Proposed Settlement and Dismissal with Prejudice of Derivative Action (the "Notice"), a copy of which is attached hereto as an...

More
Aug 17, 2020
Lannett Signs Agreement To Be Exclusive Distributor Of Generic Flovent® Diskus®

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of Flovent® Diskus® (Fluticasone...

More
Aug 3, 2020
Lannett Announces Launch Of FDA Approved Levothyroxine Tablets

Lannett Company, Inc. (NYSE: LCI) today announced the launch of Cediprof, Inc.'s FDA approved Levothyroxine Sodium Tablets USP, under the companies recently announced interim exclusive supply and...

More
Jul 27, 2020
Lannett To Launch Levorphanol Tablets

Lannett Company, Inc. (NYSE: LCI) today announced that it will soon launch Levorphanol Tablets 2 mg, a partnered product. Lannett entered into an exclusive U.S. distribution agreement for...

More
Jul 23, 2020
Lannett Launches Mexiletine HCl Capsules

Lannett Company, Inc. (NYSE: LCI) today announced that it has launched Mexiletine Hydrochloride Capsules 150 mg, 200 mg and 250 mg, a partnered product. Mexiletine Hydrochloride Capsules is the...

More
Jul 16, 2020
Lannett And Cediprof Announce Exclusive Distribution Agreement For An Approved Levothyroxine

Lannett Company, Inc. (NYSE: LCI) and Cediprof, Inc., a part of the Neolpharma Pharmaceutical Group family of companies, today said that the companies have entered into an interim exclusive supply...

More
Jul 13, 2020
Lannett Announces Restructuring, Cost Reduction Initiatives

Lannett Company, Inc. (NYSE: LCI) today announced a restructuring and cost savings plan. The initiatives include consolidating the research and development (R&D) function into a single location in...

More
Jun 11, 2020
Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting

Lannett Company, Inc. (NYSE: LCI) today said that representatives from the company spoke with and received guidance from the U.S. Food and Drug Administration (FDA) on the clinical advancement...

More
May 6, 2020
Lannett Announces Fiscal 2020 Third-Quarter Financial Results

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 third quarter ended March 31, 2020. "I am incredibly proud of the effort and dedication of all of our...

More
1-25      26-50      51-75      76-100      101-125      126-150      151-175      176-200      201-225      226-250      251-275      276-300      301-325      326-350      351-375      376-400      401-425      426-450      451-475      476-500      501-525      526-550      551-575      576-600      601-625      626-650      651-671
Price Data
NYSELCI